Evidence map›Paper›PMID 26622852›Full record

ArticleOncology letters2015

Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.

Kai-Chang Zhu, Jian-Mei Sun, Jian-Guo Shen, Ji-Zhong Jin, Feng Liu, Xiao-Lin Xu, Lin Chen, Lin-Tao Liu, Jia-Ju Lv

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Role of Phytoconstituents in Cancer Treatment: A Review.Recent advances in food, nutrition & agriculture · 2024
    Review
  4. Article
  5. Bioactive Compounds fromLife (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Anti-Cancer Potential of Afzelin towards AGS Gastric Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Kai-Chang ZhuDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China ; Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Jian-Mei SunDepartment of Neonatology, Tongji Hospital, Tongji University, Shanghai 200065, P.R. China.
Jian-Guo ShenDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Ji-Zhong JinDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Feng LiuDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Xiao-Lin XuDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Lin ChenDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Lin-Tao LiuDepartment of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China.
Jia-Ju LvDepartment of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China.
Shanghai Sixth People's Hospital · CNShandong Provincial Hospital · CNShandong University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer presents high occurrence worldwide. Medicinal plants are a major source of novel and potentially therapeutic molecules; therefore, the aim of the present study was to investigate the possible anti-prostate cancer activity of afzelin, a flavonol glycoside that was previously isolated from

Indexed as

afzelinG0 phaseLIM domain kinase 1LNCaP cellsPC-3 cellsprostate cancer

Identifiers

PMID26622852
PMCPMC4580011
OpenAlexW1889558574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.